Luopu Pharmaceutical Co., Ltd. was incorporated in Zhejiang Administration for Industry and Commerce on May 6, 20 10 with the registration number of 1997. The legal representative is Xu Wencai, whose business scope includes general business items: pharmaceutical industry investment, network investment, equity investment management, etc.
On March 17, 2022, official website, the organization of the Geneva Pharmaceutical Patent Pool announced that 35 companies, including Roper Pharmaceutical Co., Ltd., were allowed to imitate the raw materials or preparations of nemativir, one of the ingredients of Pfizer COVID-19's oral drug paciclovir. Roper Pharmaceutical Co., Ltd. can produce raw materials and preparations.
Luopu Pharmaceutical Co., Ltd. is a national key high-tech enterprise and a key enterprise in Zhejiang pharmaceutical industry. It was listed on the main board of Shenzhen Stock Exchange on 200 1, and it is a platform for the integration of industry and finance in the pharmaceutical industry of Hengdian Group. In the latest ranking list of the top 100 pharmaceutical industries of the Ministry of Industry and Information Technology, it ranks among the top 50.
The company's main business covers API intermediates, contract R&D and production services (CDMO), preparations and import and export trade. The main varieties involved are as follows: API intermediates: including oral cephalosporin series, oral penicillin series, veterinary drug API intermediates series, psychiatric series, cardiovascular and cerebrovascular series. Contract R&D and Production (CDMO): including commercial products with expired patents, commercial products within patent period and products within clinical period. Preparations: Preparation products include anti-infection, cardiovascular and cerebrovascular diseases and anti-tumor.
Won the 20021annual "China listed companies 100 top summit forum" and "China high-growth enterprises 100 top". In addition, the company has also been selected as the "Eagle Action" cultivating enterprise in Zhejiang Province and the "Pilot Unit of Integrated Development of Advanced Manufacturing and Modern Service Industry" by the National Development and Reform Commission. The multi-faceted support of national policies will empower enterprises for high-quality innovation and development.
The business scope is pharmaceutical industry investment, network investment, equity investment management, research and development and transfer of biopharmaceutical technology, and domestic trade; Engaged in import and export business.